Tesamorelin (also known as TH9507) is a GHRH analog approved for HIV-associated lipodystrophy and studied for visceral fat. This page covers what the published research does — and does not — establish about it in relation to growth-hormone support.
Tesamorelin is discussed in the context of growth-hormone support because of its mechanism, not because the literature studies it for that outcome directly. The research we can point to covers Visceral fat reduction, Metabolic health, Cognitive studies. Treat any claim beyond that with scepticism.
Research status: FDA-approved for a specific indication; studied off-label.
How Tesamorelin is thought to work
Tesamorelin is a stabilized GHRH analog that boosts the body's growth-hormone axis. Unlike most research peptides, it is FDA-approved for a specific indication — reducing excess visceral (abdominal) fat in people with HIV-associated lipodystrophy — and has also been studied for cognitive and metabolic outcomes.
What it does not establish
Prescription medication for its approved use. Affects growth hormone axis.
Nothing on this page is a recommendation to use Tesamorelin, and Selpho publishes no dosing, reconstitution or sourcing information. Read how we decide what goes in the library.
Commonly researched alongside
A selective growth-hormone secretagogue studied for its clean GH-release profile.
Other peptides researched for Growth Hormone
A growth-hormone-releasing hormone analog studied for GH support.
A selective growth-hormone secretagogue studied for its clean GH-release profile.
One of the earliest GHRH analogs, historically used to assess GH function.
An early GH-releasing peptide known for strongly stimulating appetite.
A potent GH secretagogue also studied for cardiac tissue effects.
An orally active growth-hormone secretagogue (a non-peptide) studied for GH/IGF-1.
Frequently asked questions
Not directly. Tesamorelin is discussed in the context of growth-hormone support because of its mechanism, but the research we can point to studies it for visceral fat reduction, metabolic health, cognitive studies rather than for this outcome specifically. FDA-approved for a specific indication; studied off-label. Selpho does not provide dosing or medical advice.
FDA-approved for a specific indication; studied off-label.
Prescription medication for its approved use. Affects growth hormone axis. Always speak to a licensed healthcare professional before considering any peptide.
It is FDA-approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Other uses are off-label or investigational.
Its approved evidence is specific to HIV-associated visceral fat. Broader use is not established and it affects the growth-hormone axis.
Is Tesamorelin right for your situation?
Describe your goals and the free Peptide Advisor will match them against the research — no signup, no sales pitch.
Ask the Advisor — freeThis page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.